. Author manuscript; available in PMC: 2014 Jul 1.

Published in final edited form as: Arterioscler Thromb Vasc Biol. 2013 May 2;33(7):1728–1733. doi: 10.1161/ATVBAHA.112.301174

Table 5.

Reclassification matrix for 10-year mortality

Without Biomarkers	With TNFRII, ICAM-1, interleukin-6
	<5%	5-10%	>10%	Total
*Participants surviving*
<5%	989 (92.3)	73 (6.8)	9 (0.8)	1071
5-10%	188 (31.1)	335 (55.4)	82 (13.6)	605
>10%	9 (0.9)	179 (17.5)	833 (81.6)	1021
Total	1186	587	924	2697

*Participants who died*
<5%	19 (73.1)	4 (15.4)	3 (11.5)	26
5-10%	5(13.2)	19 (50.0)	14 (36.8)	38
>10%	1 (0.4)	10(3.6)	263 (96.0)	274
Total	25	33	280	338

Analyses were censored at 10-year follow-up. Provided are the number of individuals and row percent. Relative Net-reclassification improvement was 9.4%, P<0.0001.

Green shaded cells represent favorable reclassification, red shaded cells unfavorable reclassification.